Rapport sur le marché du traitement des lésions de la moelle épinière au Moyen-Orient et en Afrique - Tendances de l'industrie et prévisions jusqu'en 2032

Middle East And Africa Spinal Cord Injury Treatment Market

Taille du marché en milliards USD

TCAC : 3.90 %

USD 249.49 Million USD 337.35 Million 2024 2032

Période de prévision	2025 –2032
Taille du marché (année de référence)	USD 249.49 Million
Taille du marché (année de prévision)	USD 337.35 Million
TCAC	3.90 %
Principaux acteurs du marché	Novartis AG Pfizer Inc. Medtronic Zimmer Biomet Abbott

Middle East and Africa Spinal Cord Injury Treatment Market, By Type (Non-Operative Management and Operative Management), Injury Type (Complete Spinal Cord Injuries and Partial Spinal Cord Injuries), Level of Injury (Cervical Spinal Cord Injuries, Thoracic Spinal Cord Injuries, Lumbar Spinal Cord Injuries, and Sacral Spinal Cord Injuries), Gender (Male and Female), End User (Hospitals, Trauma Centers, Specialty Clinics, Clinics, Ambulatory and Research Centers, and Others) - Industry Trends & Forecast To 2032

Middle East and Africa Spinal Cord Injury Treatment Market Analysis

According to an article published by International Journal of Health Policy and Management in may 2021, Partnership approaches are becoming increasingly popular within the spinal cord injury (SCI) health research field, creating opportunities to explore and learn from the successes of SCI research partnership champions. The growing collaboration and expanding partnerships in the Middle East and Africa spinal cord injury treatment market are pivotal in driving innovation, advancing research, and improving patient care. By combining expertise from diverse sectors, these collaborations foster the development of novel therapies, enhance rehabilitation techniques, and improve medical devices.

Middle East and Africa Spinal Cord Injury Treatment Market Size

Middle East and Africa spinal cord injury treatment market is expected to reach USD 337.35 million by 2032 from USD 249.49 million in 2024, growing at a CAGR of 3.9% in the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include import export analysis, production capacity overview, production consumption analysis, price trend analysis, climate change scenario, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework.

Middle East and Africa Spinal Cord Injury Treatment Market Trends

“Growing Collaboration and Expanding Partnerships”

In the evolving field of spinal cord injury (SCI) research, a notable trend is the increasing collaboration among academic institutions, research organizations, pharmaceutical companies, and medical device manufacturers. These alliances facilitate the sharing of expertise, resources, and funding to tackle SCI’s inherent challenges—such as limited regenerative capacity and the complexities of treatment. By uniting diverse strengths, these partnerships are accelerating the development of innovative therapies, including stem cell treatments, neuroprosthetics, and gene therapies. Moreover, industry stakeholders are joining forces to enhance rehabilitation programs, refine mobility aids, and improve diagnostic tools. An emerging trend is the collective sharing of clinical data, which deepens our understanding of SCI’s pathophysiology and helps tailor personalized treatment strategies. In addition, collaborations between Middle East and Africa healthcare providers and policy-makers are driving reforms that improve access to cutting-edge treatments and ensure their affordability. Overall, these collaborative trends not only raise the standard of care but also propel the worldwide effort to cure spinal cord injuries, ultimately transforming the lives of those affected.

Report Scope and Middle East and Africa Spinal Cord Injury Treatment Market Segmentation

Attributes	Middle East and Africa Spinal Cord Injury Treatment Market Insights
Segments Covered	By Type: Non-Operative Management, and Operative Management By Injury Type: Complete Spinal Cord Injuries, and Partial Spinal Cord Injuries By Level of Injury: Cervical Spinal Cord Injuries, Thoracic Spinal Cord Injuries, Lumbar Spinal Cord Injuries, and Sacral Spinal Cord Injuries By Gender: Male and Female By End User: Hospitals, Trauma Centers, Specialty Clinics, Clinics, Ambulatory and Research Centers, and Others
Region Covered	Saudi Arabia, U.A.E., South Africa, Egypt, Kuwait, Israel, and Rest of Middle East and Africa
Key Market Players	Novartis AG (Switzerland), Pfizer Inc. (U.S.), Medtronic (Ireland), Zimmer Biomet (U.S.), Abbott (U.S.), Amneal Pharmaceuticals LLC (U.S.), Sanofi (France), Axonis Therapeutics (U.S.), Zydus Group (India), Lineage Cell Therapeutics, Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Camber Pharmaceuticals, Inc. (U.S.), Dr. Reddy’s Laboratories Ltd. (India), Teva Pharmaceuticals USA, Inc. (U.S.), Niksan Pharmaceuticals (India), Covis Pharma GmbH (Germany), Indian Spinal Injuries Centre (India), Jubilant Cadista Pharmaceuticals Inc. (U.S.), Johnson & Johnson (U.S.), Nervgen Pharma Corp. (Canada), Advacare Pharma (U.S.), Boston Scientific (U.S.), Vasudha Pharma (India), Enomark (India), Glenmark Pharmaceuticals U.S. Inc. (U.S.), Inova Pharmaceuticals (U.S.), Globus Medical (U.S.), Zimvie Inc. (U.S.), and Bioaxone (U.S.)
Market Opportunities	Rising Geriatric Population Rising Incidence of Traumatic Injuries
Value Added Data Infosets	In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include import export analysis, production capacity overview, production consumption analysis, price trend analysis, climate change scenario, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework.

Middle East and Africa Spinal Cord Injury Treatment Market Definition

The Middle East and Africa spinal cord injury treatment refers to the medical care and interventions provided to individuals with spinal cord injuries (SCI) in the region. SCI treatments aim to minimize neurological damage, improve motor and sensory function, and enhance the quality of life for patients. This includes both surgical procedures, such as spinal stabilization and decompression, and non-surgical approaches like physical therapy, rehabilitation, and the use of assistive technologies. With increasing awareness and advancements in healthcare infrastructure, the demand for specialized SCI care has grown in the region, alongside initiatives to enhance research and patient support systems.

Middle East and Africa Spinal Cord Injury Treatment Market Dynamics

Drivers

Growing Collaboration and Expanding Partnerships

As SCI research continues to evolve, collaboration among academic institutions, research organizations, pharmaceutical companies, and medical device manufacturers has become increasingly vital. These partnerships enable the pooling of expertise, resources, and funding to overcome the significant challenges associated with spinal cord injuries, including limited regeneration potential and the complexity of treatment. Through collaborative efforts, the development of innovative therapies, such as stem cell treatments, neuroprosthetics, and gene therapies, has been accelerated. In addition, industry players are collaborating to create more effective rehabilitation programs, improve medical devices like mobility aids, and establish better diagnostic tools. Expanding partnerships also provide a platform for sharing clinical data, which is essential for enhancing understanding of SCI's pathophysiology and optimizing personalized treatment strategies. Moreover, collaborations between Middle East and Africa healthcare providers and policy-makers help drive healthcare reforms, improve access to cutting-edge treatments, and ensure the affordability of SCI therapies. Ultimately, these growing partnerships not only improve the quality of care but also contribute to the Middle East and Africa effort to find a cure for spinal cord injuries, driving innovation and improving the lives of those affected by SCI worldwide.

For instance,

In May 2021, according to an article published by International Journal of Health Policy and Management, Partnership approaches are becoming increasingly popular within the spinal cord injury (SCI) health research field, creating opportunities to explore and learn from the successes of SCI research partnership champions
In May 2023, according to an article published in the TechTarget Network, the Reeve Foundation and University of Alberta partnership aimed to facilitate open data sharing in spinal cord injury research to promote value, shared knowledge, and data transparency. The University of Alberta and the Reeve Foundation have launched a joint three-year project to facilitate open data sharing through the Open Data Commons for Spinal Cord Injury (ODC-SCI)
The growing collaboration and expanding partnerships in the Middle East and Africa spinal cord injury treatment market are pivotal in driving innovation, advancing research, and improving patient care. By combining expertise from diverse sectors, these collaborations foster the development of novel therapies, enhance rehabilitation techniques, and improve medical devices. As a result, SCI patients benefit from more effective, personalized treatments and better outcomes. With continued investment in partnerships, the market is poised to make significant strides in both the treatment and potential cure for spinal cord injuries, ultimately improving the quality of life for millions of individuals worldwide.

Technological Advancements In Treatment Methods

Innovations such as stem cell therapy, neuroprosthetics, and advanced neurostimulation techniques are significantly improving recovery prospects for SCI patients. The development of robotic exoskeletons and artificial intelligence for personalized treatment plans enhances rehabilitation outcomes. In addition, breakthroughs in biomaterials for spinal cord regeneration and gene editing technologies, like CRISPR, offer new hope for restoring lost functions. These cutting-edge treatments are not only boosting the effectiveness of therapies but also expanding the market as more patients seek advanced solutions to improve quality of life.

For instance,

In October 2023, according to an article published by NCBI, technological advancements in SCI treatment, such as the development of flexible biomaterials like hydrogels, address challenges in tissue repair. These materials support spinal cord regeneration by adapting to lesion shapes, preventing fibrosis, and promoting axonal growth
In July 2021, according to an article published by NCBI, technological advancements in SCI treatment, such as Epidural Electrical Stimulation (EES), have shown promising results in both preclinical and clinical studies. EES enhances sensory and motor functions following spinal cord injury, highlighting its potential to improve recovery outcomes. This innovation underscores the growing role of electrical stimulation in SCI rehabilitation
Les avancées technologiques transforment le traitement des lésions médullaires, offrant un nouvel espoir aux patients et améliorant significativement les résultats de leur rétablissement. Les innovations en matière de thérapie par cellules souches, de neuroprothèses, de neurostimulation et de traitements personnalisés basés sur l'intelligence artificielle améliorent les perspectives de réadaptation. Les avancées dans les biomatériaux et l'édition génétique repoussent les limites de la régénération médullaire, restaurant les fonctions perdues et améliorant la qualité de vie. Grâce à l'évolution continue de ces traitements de pointe, le marché des traitements des lésions médullaires est appelé à croître, offrant des solutions toujours plus avancées et efficaces aux personnes qui en ont besoin.

Contraintes/Défis

Risques potentiels, effets secondaires et complications des traitements de la moelle épinière

Certaines options thérapeutiques actuelles pour les lésions de la moelle épinière, notamment les interventions chirurgicales et les traitements médicamenteux, comportent divers effets secondaires, complications et risques à long terme. Bien qu'essentielles pour certaines lésions, les interventions chirurgicales peuvent parfois entraîner une infection, un saignement ou des lésions des tissus environnants, ce qui peut aggraver l'état du patient. De plus, des complications neurologiques, telles qu'une paralysie ou une perte des fonctions motrices, sont toujours possibles suite à l'intervention. Concernant les traitements médicamenteux, des effets secondaires tels que nausées, vertiges et dépendance aux analgésiques peuvent compliquer le processus de guérison. Dans les cas plus graves, les médicaments utilisés pour gérer la douleur ou l'inflammation peuvent entraîner des problèmes à long terme tels que des lésions organiques ou une immunosuppression. Ces risques peuvent dissuader de nombreux patients d'envisager ces options thérapeutiques, notamment s'ils craignent une aggravation potentielle de leur état de santé ou l'apparition de nouvelles complications. Par conséquent, certains patients peuvent choisir d'éviter ou de retarder ces traitements, optant pour des thérapies alternatives ou des approches non conventionnelles n'ayant pas nécessairement fait l'objet d'essais cliniques approfondis. Cette réticence à recourir aux traitements traditionnels peut impacter le rétablissement du patient, retardant potentiellement les améliorations ou diminuant l'efficacité globale du traitement. De plus, pour les patients confrontés aux conséquences à vie d'une lésion médullaire, le fardeau des risques et complications liés au traitement peut aggraver le fardeau physique et émotionnel, rendant la décision de poursuivre le traitement encore plus difficile.

Par exemple

En décembre 2024, selon un article publié par le NCBI, une lésion médullaire chronique ou oncologique peut se manifester par des symptômes tels que des douleurs dorsales persistantes, des signes constitutionnels (perte de poids, fièvre, anorexie) et une faiblesse sensorimotrice progressive. À mesure que la lésion se développe, des déficits moteurs, notamment une perte de préhension et de mobilité, peuvent apparaître. Les facteurs de risque incluent le tabagisme, un traitement anticancéreux antérieur, une exposition à la tuberculose, une intervention chirurgicale récente et une immunosuppression.
En janvier 2025, selon un article publié par le NCBI, les lésions de la moelle épinière (LME) peuvent entraîner diverses complications, notamment pneumonie, troubles circulatoires, raideurs musculaires, dysréflexie autonome, escarres, douleurs neurogènes, troubles vésicaux et intestinaux, dysfonction sexuelle et dépression. Les patients nécessitent une surveillance attentive, des mesures préventives et des traitements spécialisés, tels que des médicaments, de la kinésithérapie et un soutien émotionnel, pour gérer ces difficultés.

Bien que les traitements chirurgicaux et pharmaceutiques soient essentiels à la guérison des lésions médullaires, ils comportent des risques importants, notamment des infections, des complications neurologiques et des effets secondaires à long terme. Ces inconvénients potentiels découragent souvent les patients de poursuivre ou de s'engager pleinement dans ces traitements, par crainte de dommages supplémentaires ou d'une diminution de leur qualité de vie. Par conséquent, les patients peuvent se tourner vers des thérapies alternatives, dont l'efficacité peut s'avérer insuffisante. Cela souligne la nécessité de disposer d'options thérapeutiques plus sûres et plus efficaces, ainsi que l'importance d'une prise en charge globale qui concilie risques potentiels et chances de guérison, afin de mieux accompagner les patients atteints de lésion médullaire.

Compréhension limitée des traitements des lésions de la moelle épinière

La compréhension limitée de la physiopathologie complexe des lésions de la moelle épinière (LME) freine considérablement le développement de traitements efficaces et représente un défi majeur pour le marché du traitement des LME au Moyen-Orient et en Afrique. Les LME impliquent une cascade d'événements aux niveaux moléculaire et cellulaire, entraînant des lésions neuronales, une inflammation et la formation de cicatrices gliales, autant de facteurs contribuant à des déficits fonctionnels. L'absence de compréhension complète de ces processus complexes complique l'identification de cibles thérapeutiques précises et la conception d'interventions susceptibles de favoriser efficacement la régénération neuronale et la récupération fonctionnelle. Par conséquent, de nombreux traitements actuels se concentrent sur la gestion des symptômes et la prévention des complications plutôt que sur le traitement des causes sous-jacentes des LME.

Par exemple,

En octobre 2020, selon un article publié dans la Bibliothèque nationale de médecine, des facteurs hétérogènes tels que des caractéristiques complexes, des incohérences abondantes et des conséquences physiopathologiques complexes après une lésion de la moelle épinière sont les principales raisons de la mauvaise compréhension et de l'échec du traitement des lésions de la moelle épinière.
En février 2023, selon un article publié par l'Oxford University Press, la physiopathologie des LME est complexe et multiforme, et donc les traitements individuels agissant sur un aspect ou un processus spécifique sont inadéquats pour provoquer une régénération neuronale et une récupération fonctionnelle après une LME

Ce manque de connaissances freine également le développement de stratégies thérapeutiques personnalisées. Les lésions médullaires ne sont pas une affection uniforme, et chaque patient présente des degrés variables de gravité des lésions, de déficiences neurologiques et de limitations fonctionnelles. Sans une compréhension approfondie des mécanismes spécifiques à l'origine des lésions de chaque patient, il devient difficile d'adapter les plans de traitement à leurs besoins individuels. Cela peut entraîner des résultats thérapeutiques sous-optimaux et une baisse de la satisfaction des patients. De plus, cette compréhension limitée des lésions médullaires freine le développement d'outils diagnostiques et de biomarqueurs précis, ce qui complique le suivi de l'efficacité du traitement et la prédiction des résultats à long terme. Relever ce défi nécessite des investissements importants en recherche fondamentale et translationnelle afin de décrypter les complexités des lésions médullaires et d'ouvrir la voie à des thérapies plus efficaces et ciblées.

Opportunités

Augmentation de la population gériatrique

Avec l'âge, la densité osseuse, la force musculaire et l'équilibre diminuent souvent, ce qui les rend plus vulnérables aux chutes, une cause majeure de lésion médullaire dans cette tranche d'âge. Cette évolution démographique se traduit par une augmentation du nombre de patients nécessitant des soins spécialisés et des services de réadaptation. La demande porte non seulement sur des soins immédiats après une blessure, mais aussi sur la prise en charge à long terme des complications liées à une lésion médullaire, telles que la douleur, la spasticité et les escarres, qui nécessitent souvent une attention médicale continue.

Par exemple,

Selon un article publié par le Population Reference Bureau en janvier 2024, le nombre d'Américains âgés de 65 ans et plus devrait passer de 58 millions en 2022 à 82 millions en 2050 (soit une augmentation de 47 %), et leur part dans la population totale devrait passer de 17 % à 23 %. L'augmentation de la population âgée, sujette aux lésions de la colonne vertébrale, stimulera la demande et développera le marché du traitement des lésions de la colonne vertébrale.
En octobre 2019, selon un article publié par la Bibliothèque nationale de médecine, les niveaux d'incapacité fonctionnelle, ainsi que les difficultés fonctionnelles, les activités de la vie quotidienne et la capacité physique, ont été identifiés dans 60 % des études. Cette revue a révélé une prévalence élevée de lombalgie et d'incapacité fonctionnelle chez les personnes âgées.

Moreover, the geriatric population often presents unique challenges in SCI treatment, necessitating tailored approaches and innovative solutions. Older individuals may have pre-existing conditions that complicate treatment plans and require specialized care strategies. This situation drives the need for research and development in age-specific therapies and assistive devices. Additionally, the focus extends beyond merely addressing the physical aspects of SCI to encompass mental health support, social integration, and enhanced quality of life for elderly patients. Therefore, the rising geriatric population acts as a catalyst for the growth and diversification of the SCI treatment market, compelling stakeholders to innovate and provide comprehensive care solutions tailored to the needs of older adults.

Rising Incidence of Traumatic Injuries

Traumatic injuries, such as those from motor vehicle accidents, falls, sports injuries, and violence, presents a significant opportunity for the global Spinal Cord Injury (SCI) treatment market. As the frequency of these incidents increases, so does the number of individuals suffering from spinal cord injuries, thereby expanding the potential patient base for treatment. This trend is particularly notable among younger populations, who are often more prone to engaging in high-risk activities. The consequent demand for effective and advanced treatment options, including emergency care, surgical interventions, rehabilitation services, and assistive technologies, drives growth in the SCI treatment market. Manufacturers of medical devices, pharmaceutical companies, and healthcare providers can capitalize on this trend by developing and marketing innovative treatments and services tailored to the needs of traumatic SCI patients.

For instance,

In June 2022, according to an article published by the National Library of Medicine, the incidence and burden of SCI has increased over the last 30 years. Males and the elderly were affected to a greater degree than females and younger individuals. falls and road injuries were the leading causes of the most of the SCIs.
In April 2024, according to an article published by the World Health Organization, globally, over 15 million people are living with spinal cord injury (SCI). Most SCI cases are due to trauma, including falls, road traffic injuries or violence.

The rising incidence of traumatic injuries fuels significant expansion in the global SCI treatment market, creating opportunities across various healthcare sectors. Focusing on innovative and effective solutions tailored to the specific needs of this patient population will be crucial. The ongoing development and provision of advanced treatments are paramount in meeting the growing demand and improving outcomes for individuals affected by spinal cord injuries.

Incorporation of Artificial Intelligence and Big Data Analytics

By leveraging AI-powered algorithms and vast amounts of patient data, researchers can identify patterns and correlations that were previously unknown, leading to the development of more effective treatment strategies and personalized care plans. AI can assist in predicting treatment outcomes, optimizing rehabilitation plans, and streamlining patient care processes. Additionally, the use of machine learning algorithms can help in identifying high-risk patients, enabling proactive interventions and reducing the likelihood of complications. This data-driven approach can also facilitate the development of more accurate diagnostic tools and predictive models, ultimately improving the quality of care for SCI patients.

For instance,

In April 2023, according to an article published by the National Library of Medicine, in acute spinal cord injury care, generative AI can analyze vital signs, lab results, and other patient data to predict the likelihood of pressure sores, urinary tract infections, or other complications. This can help clinicians intervene early, which can improve patient outcomes and reduce healthcare costs
In April 2023, according to an article published by the European Journal of Radiology, Early AI applications in spine have demonstrated remarkable utility in the assessment of the focal lesions. For example, some algorithms have been able to detect early compressive myelopathy changes and demyelinating lesions in the spinal cord, which are otherwise occult on normally appearing MR images

By leveraging AI-driven insights, manufacturers can design and engineer more effective and adaptive assistive technologies that cater to the unique needs of individual patients. Furthermore, the use of telemedicine and remote monitoring platforms can enhance patient engagement and compliance, while AI-powered chatbots and virtual assistants can provide 24/7 support and guidance to patients. By embracing AI and Big Data Analytics, stakeholders in the SCI treatment market can revolutionize patient care, enhance the efficiency of healthcare services, and drive growth in the industry. This convergence of technology and healthcare can lead to the creation of more effective treatment modalities, improved patient outcomes, and a more personalized approach to SCI care.

Middle East and Africa Spinal Cord Injury Treatment Market Scope

The market is segmented on the basis of type, injury type, level of injury, gender, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

Non-Operative Management
- Therapy
  - Rehabilitation Therapy
    - Physical
    - Occupational Or Speech Therapy
  - Intrathecal Baclofen Therapy (Ibt)
- Medication
  - Anticonvulsants
  - Corticosteroids
    - Methylprednisolone
    - Dexamethasone
  - Antidepressants
    - ISRS (inhibiteurs sélectifs de la recapture de la sérotonine)
    - Snris (inhibiteurs de la recapture de la sérotonine et de la noradrénaline)
    - médicaments tricycliques
    - Médicaments contre l'anxiété
  - Antispasmodiques et relaxants musculaires
    - Benzodiazépines
    - Agonistes alpha-2
    - Autres agonistes Gaba
    - Autres
  - AINS
    - Ibuprofène
    - Naproxène
    - Autres
  - Analgésiques narcotiques
  - Antibiotiques
    - β-lactamines (pénicillines, céphalosporines)
    - Macrolides (azithromycine, érythromycine)
    - Minocycline (classe des tétracyclines)
    - Dapsone
    - Autres (fluoroquinolones, aminoglycosides, etc.)

Par type de médicament

Générique
De marque
- Médrol
- Liorésal
- Lyrica
- Neurontin
- Zanaflex
- Gralise
- Horizant
- Rilutek

Par voie d'administration

Oral
- Comprimés
- Capsules
Parentérale
Patchs transdermiques
Gestion opérationnelle
- Chirurgie de décompression
  - Discectomie ou microdiscectomie
  - Laminectomie
  - Microdiscectomie postérieure/Microdécompression
  - Foraminectomie
  - Chirurgie reconstructive de la colonne vertébrale
  - Laminectomie cervicale postérieure
  - Laminotomie
- Remplacement du disque
  - Implantation de disque cervical artificiel
  - Chirurgie du disque artificiel/arthroplastie vertébrale
- Ablation des disques et des facettes articulaires
  - Discectomie cervicale antérieure
  - Fusion vertébrale
    - Fusion vertébrale lombaire
    - Fusion cervicale vertébrale
    - Fusion de sextants
  - Fascétectomie médiale
    - Retirer l'articulation à deux facettes
    - Retirer une facette articulaire
- Autres

Type de blessure

Lésions complètes de la moelle épinière
Lésions partielles de la moelle épinière

Niveau de blessure

Lésions de la moelle épinière cervicale
- Lésions complètes de la moelle épinière
- Lésions partielles de la moelle épinière
Lésions de la moelle épinière thoracique
- Lésions complètes de la moelle épinière
- Lésions partielles de la moelle épinière
Lésions de la moelle épinière lombaire
- Lésions complètes de la moelle épinière
- Lésions partielles de la moelle épinière
Lésions de la moelle épinière sacrée
- Lésions complètes de la moelle épinière
- Lésions partielles de la moelle épinière

Genre

Mâle
- Adulte
- gériatrique
- Enfants
Femelle
- Adulte
- gériatrique
- Enfants

Utilisateur final

Hôpitaux
Centres de traumatologie
Cliniques spécialisées
Cliniques
Centres ambulatoires et de recherche
Autres

Canal de distribution

Pharmacie de l'hôpital
Pharmacie de détail
Pharmacie en ligne

Analyse régionale du marché du traitement des lésions de la moelle épinière au Moyen-Orient et en Afrique

Le marché est analysé et des informations sur la taille du marché et les tendances sont fournies par pays, type, type de blessure, niveau de blessure, sexe, utilisateur final et canal de distribution comme référencé ci-dessus.

Les pays couverts par le marché sont l’Arabie saoudite, les Émirats arabes unis, l’Afrique du Sud, l’Égypte, Israël et le reste du Moyen-Orient et de l’Afrique.

L'Afrique du Sud domine le marché du traitement des lésions de la moelle épinière au Moyen-Orient et en Afrique grâce à son infrastructure de soins de santé avancée, ses centres de réadaptation établis, sa sensibilisation croissante et la recherche médicale croissante sur les lésions de la moelle épinière.

L'Arabie saoudite est le marché du traitement des lésions de la moelle épinière qui connaît la croissance la plus rapide au Moyen-Orient et en Afrique, en raison d'investissements importants dans les infrastructures de santé, de technologies médicales avancées et de l'attention croissante du gouvernement portée aux soins spécialisés.

La section pays du rapport présente également les facteurs d'impact sur les marchés individuels et les évolutions réglementaires nationales qui influencent les tendances actuelles et futures du marché. Des données telles que l'analyse des chaînes de valeur en aval et en amont, les tendances techniques, l'analyse des cinq forces de Porter et les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour chaque pays. De plus, la présence et la disponibilité des marques du Moyen-Orient et d'Afrique, ainsi que les difficultés rencontrées en raison de la forte ou de la faible concurrence des marques locales et nationales, de l'impact des tarifs douaniers nationaux et des routes commerciales, sont prises en compte lors de l'analyse prévisionnelle des données nationales.

Part de marché du traitement des lésions de la moelle épinière au Moyen-Orient et en Afrique

Le paysage concurrentiel du marché fournit des détails par concurrent. Il comprend la présentation de l'entreprise, ses données financières, son chiffre d'affaires, son potentiel de marché, ses investissements en recherche et développement, ses nouvelles initiatives commerciales, sa présence au Moyen-Orient et en Afrique, ses sites et installations de production, ses capacités de production, ses forces et faiblesses, le lancement de nouveaux produits, leur ampleur et leur portée, ainsi que la domination de ses applications. Les données ci-dessus ne concernent que les activités des entreprises par rapport à leur marché.

Les leaders du marché du traitement des lésions de la moelle épinière au Moyen-Orient et en Afrique opérant sur le marché sont :

Novartis AG (Suisse)
Pfizer Inc. (États-Unis)
Medtronic (Irlande)
Zimmer Biomet (États-Unis)
Abbott (États-Unis)
Amneal Pharmaceuticals LLC (États-Unis)
Sanofi (France)
Axonis Therapeutics (États-Unis)
Groupe Zydus (Inde)
Lineage Cell Therapeutics, Inc. (États-Unis)
Sun Pharmaceutical Industries Ltd. (Inde)
Camber Pharmaceuticals, Inc. (États-Unis)
Dr. Reddy's Laboratories Ltd. (Inde)
Teva Pharmaceuticals USA, Inc. (États-Unis)
Niksan Pharmaceuticals (Inde)
Covis Pharma GmbH (Allemagne)
Centre indien des traumatismes médullaires (Inde)
Jubilant Cadista Pharmaceuticals Inc. (États-Unis)
Johnson & Johnson (États-Unis)
Nervgen Pharma Corp. (Canada)
Advacare Pharma (États-Unis)
Boston Scientific (États-Unis)
Vasudha Pharma (Inde)
Enomark (Inde)
Glenmark Pharmaceuticals US Inc. (États-Unis)
Inova Pharmaceuticals (États-Unis)
Globus Medical (États-Unis)
Zimvie Inc. (États-Unis)
Bioaxone (États-Unis)

Derniers développements sur le marché du traitement des lésions de la moelle épinière au Moyen-Orient et en Afrique

En mai 2023, Abbott a annoncé que la FDA avait approuvé ses dispositifs de stimulation de la moelle épinière (SCS) pour le traitement des douleurs dorsales chroniques chez les personnes qui n'ont pas subi ou ne sont pas éligibles pour subir une chirurgie du dos, appelées douleurs dorsales non chirurgicales.
En janvier 2025, Abbott a annoncé de nouvelles données sur quatre ans démontrant le soulagement durable et à long terme que sa technologie exclusive de stimulation médullaire (SCS) BurstDR procure aux personnes souffrant de douleurs chroniques, notamment au dos et aux jambes. Ces données, qui confirment le haut niveau de satisfaction des patients vis-à-vis du traitement, représentent les résultats d'une étude de suivi pluriannuelle sur quatre ans et sont présentées lors du congrès annuel 2025 de la North American Neuromodulation (NANS), qui se tient à Orlando, en Floride.
In August 2024 , Zimmer Biomet has signed an agreement to acquire OrthoGrid Systems, expanding its hip portfolio with OrthoGrid’s AI-driven Hip AI surgical guidance platform. The acquisition includes AI-powered fluoroscopy-based systems, enhancing surgical accuracy and efficiency
In December 2020 , Camber Pharmaceuticals launched Baclofen Tablets, a generic version of Lioresal. Baclofen is used to treat muscle pain, spasms, and stiffness in conditions like multiple sclerosis and spinal cord injury. Available in 10 mg and 20 mg strengths, it provides relief by relaxing muscles and easing discomfort for patients with these conditions
In December 2020 , Globus Medical announced that it has been awarded with a group purchasing agreement with Premier, a leading group purchasing organizations in the U.S. This agreement done by the company has increased its credibility in the market leading to increased revenue in future

SKU-73732

Accédez en ligne au rapport sur le premier cloud mondial de veille économique

Cliquez sur l'image pour l'agrandir

Tableau de bord d'analyse de données interactif
Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
Accès d'analyste de recherche pour la personnalisation et les requêtes
Analyse de la concurrence avec tableau de bord interactif
Dernières actualités, mises à jour et analyse des tendances
Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence

Demande de démonstration

Table des matières

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTAL ANALYSIS

4.2 PORTERS FIVE FORCES ANALYSIS

5 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET: REGULATIONS

5.1 ONGOING COMPLIANCE AND UPDATES:

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 GROWING COLLABORATION AND EXPANDING PARTNERSHIPS

6.1.2 TECHNOLOGICAL ADVANCEMENTS IN TREATMENT METHODS

6.1.3 INCREASING HEALTHCARE EXPENDITURE

6.1.4 ENHANCED REHABILITATION TECHNIQUES

6.2 RESTRAINTS

6.2.1 POTENTIAL RISKS, SIDE EFFECTS, AND COMPLICATIONS OF SPINAL CORD TREATMENTS

6.2.2 REGULATORY BARRIERS LIMIT MARKET GROWTH BY DELAYING TREATMENT APPROVALS AND ACCESSIBILITY

6.3 OPPORTUNITIES

6.3.1 RISING GERIATRIC POPULATION

6.3.2 RISING INCIDENCE OF TRAUMATIC INJURIES

6.3.3 INCORPORATION OF ARTIFICIAL INTELLIGENCE AND BIG DATA ANALYTICS

6.4 CHALLENGES

6.4.1 LIMITED UNDERSTANDING RELATED TO SPINAL CORD INJURY TREATMENTS

6.4.2 HIGH COSTS ASSOCIATED WITH THE TREATMENTS

7 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET, BY TYPE

7.1 OVERVIEW

7.2 NON-OPERATIVE MANAGEMENT

7.2.1 THERAPY

7.2.1.1 Rehabilitation Therapy

7.2.1.1.1 PHYSICAL

7.2.1.1.2 OCCUPATIONAL OR SPEECH THERAPY

7.2.1.2 INTRATHECAL BACLOFEN THERAPY (IBT)

7.2.2 MEDICATION

7.2.2.1 ANTICONVULSANTS

7.2.2.1.1 Pregabalin

7.2.2.1.2 Gabapentin

7.2.2.1.3 Others

7.2.2.2 CORTICOSTEROIDS

7.2.2.2.1 Methylprednisolone

7.2.2.2.2 Dexamethasone

7.2.2.3 ANTIDEPRESSANTS

7.2.2.3.1 SSRIs (Selective Serotonin Reuptake Inhibitors)

7.2.2.3.2 SNRIs (Serotonin and Norepinephrine Reuptake Inhibitors)

7.2.2.3.3 Tricyclic Drugs

7.2.2.3.4 Anxiety Medications

7.2.2.4 ANTISPASMODICS AND MUSCLE RELAXANTS

7.2.2.4.1 Benzodiazepines

7.2.2.4.2 Alpha-2 Agonists

7.2.2.4.3 Other GABA Agonists

7.2.2.4.4 Others

7.2.2.5 NSAIDS

7.2.2.5.1 Ibuprofen

7.2.2.5.2 Naproxen

7.2.2.5.3 Others

7.2.2.6 NARCOTIC ANALGESICS

7.2.2.7 ANTIBIOTICS

7.2.2.7.1 β-Lactams (Penicillins, Cephalosporins)

7.2.2.7.2 Macrolides (Azithromycin, Erythromycin)

7.2.2.7.3 Minocycline (Tetracycline Type)

7.2.2.7.4 Dapsone

7.2.2.7.5 Others (Fluoroquinolones, Aminoglycosides, etc.)

7.2.2.8 Medrol

7.2.2.9 Lioresal

7.2.2.10 Lyrica

7.2.2.11 Neurontin

7.2.2.12 Zanaflex

7.2.2.13 Gralise

7.2.2.14 Rilutek

7.3 OPERATIVE MANAGEMENT

7.3.1 DECOMPRESSION SURGERY

7.3.1.1 Discectomy Or Microdiscectomy

7.3.1.2 Laminectomy

7.3.1.3 Posterior Microdiscectomy/ Microdecompression

7.3.1.4 Foraminectomy

7.3.1.5 Reconstructive Spinal Surgery

7.3.1.6 Posterior Cervical Laminectomy

7.3.1.7 Laminotomy

7.3.2 DISC REPLACEMENT

7.3.2.1 Artificial Cervical Disc Implantation

7.3.2.2 Artificial Disc Surgery/ Spinal Arthroplasty

7.3.3 DISC AND FACET JOINT REMOVAL

7.3.3.1 Anterior Cervical Discectomy

7.3.3.2 Spinal Fusion

7.3.3.2.1 Lumbar Spinal Fusion

7.3.3.2.2 Cervical Spinal Fusion

7.3.3.2.3 Sextant Fusion

7.3.3.3 Medial Facetectomy

7.3.3.3.1 REMOVE TWO FACET JOINT

7.3.3.3.2 REMOVE ONE FACET JOINT

8 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET, BY LEVEL OF INJURY

8.1 OVERVIEW

8.2 CERVICAL SPINAL CORD INJURIES

8.2.1 COMPLETE SPINAL CORD INJURIES

8.2.2 PARTIAL SPINAL CORD INJURIES

8.3 THORACIC SPINAL CORD INJURIES

8.3.1 COMPLETE SPINAL CORD INJURIES

8.3.2 PARTIAL SPINAL CORD INJURIES

8.4 LUMBAR SPINAL CORD INJURIES

8.4.1 COMPLETE SPINAL CORD INJURIES

8.4.2 PARTIAL SPINAL CORD INJURIES

8.5 SACRAL SPINAL CORD INJURIES

8.5.1 COMPLETE SPINAL CORD INJURIES

8.5.2 PARTIAL SPINAL CORD INJURIES

9 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET, BY INJURY TYPE

9.1 OVERVIEW

9.2 COMPLETE SPINAL CORD INJURIES

9.3 PARTIAL SPINAL CORD INJURIES

10 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET, BY GENDER

10.1 OVERVIEW

10.2 MALE

10.2.1 ADULT

10.2.2 GERIATIC

10.2.3 CHILDREN

10.3 FEMALE

10.3.1 ADULT

10.3.2 GERIATIC

10.3.3 CHILDREN

11 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET, BY END USER

11.1 OVERVIEW

11.2 HOSPITALS

11.3 TRAUMA CENTERS

11.4 SPECIALTY CLINICS

11.5 CLINICS

11.6 AMBULATORY AND RESEARCH CENTERS

11.7 OTHERS

12 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET, BY REGION

12.1 MIDDLE EAST AND AFRICA

12.1.1 SOUTH AFRICA

12.1.2 SAUDI ARABIA

12.1.3 U.A.E

12.1.4 EGYPT

12.1.5 KUWAIT

12.1.6 QATAR

12.1.7 OMAN

12.1.8 BAHRAIN

12.1.9 REST OF MIDDLE EAST AND AFRICA

13 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET: COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: GLOBAL

14 SWOT ANALYSIS

15 COMPANY PROFILE

15.1 PFIZER INC.

15.1.1 COMPANY SHARE ANALYSIS

15.1.2 REVENUE ANALYSIS

15.1.3 COMPANY SHARE ANALYSIS

15.1.4 PRODUCT PORTFOLIO

15.1.5 RECENT DEVELOPMENT

15.2 ABBOTT

15.2.1 COMPANY SNAPSHOT

15.2.2 REVENUE ANALYSIS

15.2.3 COMPANY SHARE ANALYSIS

15.2.4 PRODUCT PORTFOLIO

15.2.5 RECENT DEVELOPMENT

15.3 MEDTRONIC

15.3.1 COMPANY SNAPSHOT

15.3.2 REVENUE ANALYSIS

15.3.3 COMPANY SHARE ANALYSIS

15.3.4 PRODUCT PORTFOLIO

15.3.5 RECENT DEVELOPMENT

15.4 NOVARTIS AG

15.4.1 COMPANY SNAPSHOT

15.4.2 REVENUE ANALYSIS

15.4.3 COMPANY SHARE ANALYSIS

15.4.4 PRODUCT PORTFOLIO

15.4.5 RECENT DEVELOPMENT

15.5 ZIMMER BIOMET

15.5.1 COMPANY SNAPSHOT

15.5.2 REVENUE ANALYSIS

15.5.3 COMPANY SHARE ANALYSIS

15.5.4 PRODUCT PORTFOLIO

15.5.5 RECENT DEVELOPMENT

15.6 AMNEAL PHARMACEUTICALS LLC

15.6.1 COMPANY SNAPSHOT

15.6.2 REVENUE ANALYSIS

15.6.3 PRODUCT PORTFOLIO

15.6.4 RECENT DEVELOPMENT

15.7 AXONIS THERAPEUTICS

15.7.1 COMPANY SNAPSHOT

15.7.2 PRODUCT PORTFOLIO

15.7.3 RECENT DEVELOPMENT

15.8 ADVACARE PHARMA

15.8.1 COMPANY SNAPSHOT

15.8.2 PRODUCT PORTFOLIO

15.8.3 RECENT DEVELOPMENT

15.9 BIOAXONE BIOSCIENCES

15.9.1 COMPANY SNAPSHOT

15.9.2 PRODUCT PORTFOLIO

15.9.3 RECENT DEVELOPMENT

15.1 BOSTON SCIENTIFIC CORPORATION

15.10.1 COMPANY SNAPSHOT

15.10.2 REVENUE ANALYSIS

15.10.3 PRODUCT PORTFOLIO

15.10.4 RECENT DEVELOPMENT

15.11 COVIS PHARMA GMBH.

15.11.1 COMPANY SNAPSHOT

15.11.2 PRODUCT PORTFOLIO

15.11.3 RECENT DEVELOPMENT

15.12 CAMBER PHARMACEUTICALS, INC

15.12.1 COMPANY SNAPSHOT

15.12.2 PRODUCT PORTFOLIO

15.12.3 RECENT DEVELOPMENT

15.13 DR. REDDY’S LABORATORIES LTD

15.13.1 COMPANY SNAPSHOT

15.13.2 REVENUE ANALYSIS

15.13.3 PRODUCT PORTFOLIO

15.13.4 RECENT DEVELOPMENT

15.14 ENOMARK PHARMA

15.14.1 COMPANY SNAPSHOT

15.14.2 PRODUCT PORTFOLIO

15.14.3 RECENT DEVELOPMENT

15.15 GLENMARK PHARMACEUTICALS INC.,

15.15.1 COMPANY SNAPSHOT

15.15.2 REVENUE ANALYSIS

15.15.3 PRODUCT PORTFOLIO

15.15.4 RECENT DEVELOPMENT

15.16 GLOBUS MEDICAL

15.16.1 COMPANY SNAPSHOT

15.16.2 REVENUE ANALYSIS

15.16.3 PRODUCT PORTFOLIO

15.16.4 RECENT DEVELOPMENTS/NEWS

15.17 INOVA PHARMACEUTICALS

15.17.1 COMPANY SNAPSHOT

15.17.2 PRODUCT PORTFOLIO

15.17.3 RECENT DEVELOPMENT

15.18 INDIAN SPINAL INJURIES CENTRE

15.18.1 COMPANY SNAPSHOT

15.18.2 PRODUCT PORTFOLIO

15.18.3 RECENT DEVELOPMENT

15.19 JUBILANT CADISTA PHARMACEUTICALS INC.

15.19.1 COMPANY SNAPSHOT

15.19.2 PRODUCT PORTFOLIO

15.19.3 RECENT DEVELOPMENT

15.2 JOHNSON & JOHNSON SERVICES, INC

15.20.1 COMPANY SNAPSHOT

15.20.2 REVENUE ANALYSIS

15.20.3 PRODUCT PORTFOLIO

15.20.4 RECENT DEVELOPMENTS

15.21 LINEAGE CELL THERAPEUTICS, INC.

15.21.1 COMPANY SNAPSHOT

15.21.2 ANNUAL REVENUE

15.21.3 PRODUCT PORTFOLIO

15.21.4 RECENT DEVELOPMENT

15.22 NERVGEN PHARMA CORP.

15.22.1 COMPANY SNAPSHOT

15.22.2 REVENUE ANALYSIS

15.22.3 PRODUCT PIPELINE PORTFOLIO

15.22.4 RECENT DEVELOPMENT

15.23 NIKSAN PHARMACEUTICAL

15.23.1 COMPANY SNAPSHOT

15.23.2 PRODUCT PORTFOLIO

15.23.3 RECENT DEVELOPMENT

15.24 SUN PHARMACEUTICAL INDUSTRIES LTD.

15.24.1 COMPANY SNAPSHOT

15.24.2 REVENUE ANALYSIS

15.24.3 PRODUCT PORTFOLIO

15.24.4 RECENT DEVELOPMENT

15.25 SANOFI

15.25.1 COMPANY SNAPSHOT

15.25.2 REVENUE ANALYSIS

15.25.3 PRODUCT PORTFOLIO

15.25.4 RECENT DEVELOPMENT

15.26 TEVA PHARMACEUTICALS USA, INC.

15.26.1 COMPANY SNAPSHOT

15.26.2 REVENUE ANALYSIS

15.26.3 PRODUCT PORTFOLIO

15.26.4 RECENT DEVELOPMENT

15.27 VASUDHA PHARMA

15.27.1 COMPANY SNAPSHOT

15.27.2 PRODUCT PORTFOLIO

15.27.3 RECENT DEVELOPMENT

15.28 ZIMVIE INC.

15.28.1 COMPANY SNAPSHOT

15.28.2 REVENUE ANALYSIS

15.28.3 PRODUCT PORTFOLIO

15.28.4 RECENT NEWS

15.29 ZYDUS GROUP

15.29.1 COMPANY SNAPSHOT

15.29.2 REVENUE ANALYSIS

15.29.3 PRODUCT PORTFOLIO

15.29.4 RECENT DEVELOPMENT

16 QUESTIONNAIRE

17 RELATED REPORTS

Liste des tableaux

TABLE 1 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 2 MIDDLE EAST AND AFRICA NON-OPERATIVE MANAGEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 3 MIDDLE EAST AND AFRICA NON-OPERATIVE MANAGEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 4 MIDDLE EAST AND AFRICA THERAPY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 5 MIDDLE EAST AND AFRICA REHABILITATION THERAPY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 6 MIDDLE EAST AND AFRICA MEDICATION IN SPINAL CORD INJURY TREATMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 7 MIDDLE EAST AND AFRICA ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 8 MIDDLE EAST AND AFRICA ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 9 MIDDLE EAST AND AFRICA ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 10 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 11 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 12 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 13 MIDDLE EAST AND AFRICA ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 14 MIDDLE EAST AND AFRICA ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 15 MIDDLE EAST AND AFRICA ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 16 MIDDLE EAST AND AFRICA ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE 2018-2032 (USD THOUSAND)

TABLE 17 MIDDLE EAST AND AFRICA ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 18 MIDDLE EAST AND AFRICA ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 19 MIDDLE EAST AND AFRICA NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 20 MIDDLE EAST AND AFRICA NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 21 MIDDLE EAST AND AFRICA NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 22 MIDDLE EAST AND AFRICA ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 23 MIDDLE EAST AND AFRICA ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 24 MIDDLE EAST AND AFRICA ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 25 MIDDLE EAST AND AFRICA MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 26 MIDDLE EAST AND AFRICA BRANDED IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 27 MIDDLE EAST AND AFRICA MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 28 MIDDLE EAST AND AFRICA ORAL IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 29 MIDDLE EAST AND AFRICA OPERATIVE MANAGEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 30 MIDDLE EAST AND AFRICA OPERATIVE MANAGEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 31 MIDDLE EAST AND AFRICA DECOMPRESSION SURGERY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 32 MIDDLE EAST AND AFRICA DISC REPLACEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 33 MIDDLE EAST AND AFRICA DISC AND FACET JOINT REMOVAL IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 34 MIDDLE EAST AND AFRICA SPINAL FUSION IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 35 MIDDLE EAST AND AFRICA MEDIAL FACETECTOMY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE 2018-2032 (USD THOUSAND)

TABLE 36 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET, BY LEVEL OF INJURY, 2018-2032 (USD THOUSAND)

TABLE 37 MIDDLE EAST AND AFRICA CERVICAL SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 38 MIDDLE EAST AND AFRICA CERVICAL SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 39 MIDDLE EAST AND AFRICA THORACIC SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 40 MIDDLE EAST AND AFRICA THORACIC SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 41 MIDDLE EAST AND AFRICA LUMBAR SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 42 MIDDLE EAST AND AFRICA LUMBAR SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 43 MIDDLE EAST AND AFRICA SACRAL SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 44 MIDDLE EAST AND AFRICA SACRAL SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 45 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET, BY INJURY TYPE, 2018-2032 (USD THOUSAND)

TABLE 46 MIDDLE EAST AND AFRICA COMPLETE SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 47 MIDDLE EAST AND AFRICA PARTIAL SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 48 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREA TMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 49 MIDDLE EAST AND AFRICA MALE IN SPINAL CORD INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 50 MIDDLE EAST AND AFRICA MALE IN SPINAL CORD INJURY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 51 MIDDLE EAST AND AFRICA FEMALE IN SPINAL CORD INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 52 MIDDLE EAST AND AFRICA FEMALE IN SPINAL CORD INJURY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 53 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 54 MIDDLE EAST AND AFRICA HOSPITALS IN SPINAL CORD INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 55 MIDDLE EAST AND AFRICA TRAUMA CENTERS IN SPINAL CORD INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 56 MIDDLE EAST AND AFRICA SPECIALITY CLINICS IN SPINAL CORD INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 57 MIDDLE EAST AND AFRICA CLINICS IN SPINAL CORD INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 58 MIDDLE EAST AND AFRICA AMBULATORY AND RESEARCH CENTERS IN SPINAL CORD INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 59 MIDDLE EAST AND AFRICA OTHERS IN SPINAL CORD INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 60 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)

TABLE 61 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 62 MIDDLE EAST AND AFRICA NON-OPERATIVE MANAGEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 63 MIDDLE EAST AND AFRICA THERAPY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 64 MIDDLE EAST AND AFRICA REHABILITATION THERAPY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 65 MIDDLE EAST AND AFRICA MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 66 MIDDLE EAST AND AFRICA ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 67 MIDDLE EAST AND AFRICA ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 68 MIDDLE EAST AND AFRICA ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 69 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 70 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 71 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 72 MIDDLE EAST AND AFRICA ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 73 MIDDLE EAST AND AFRICA ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 74 MIDDLE EAST AND AFRICA ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 75 MIDDLE EAST AND AFRICA ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 76 MIDDLE EAST AND AFRICA ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 77 MIDDLE EAST AND AFRICA ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 78 MIDDLE EAST AND AFRICA NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 79 MIDDLE EAST AND AFRICA NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 80 MIDDLE EAST AND AFRICA NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 81 MIDDLE EAST AND AFRICA ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 82 MIDDLE EAST AND AFRICA ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 83 MIDDLE EAST AND AFRICA ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 84 MIDDLE EAST AND AFRICA OPERATIVE MANAGEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 85 MIDDLE EAST AND AFRICA DECOMPRESSION SURGERY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 86 MIDDLE EAST AND AFRICA DISC REPLACEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 87 MIDDLE EAST AND AFRICA DISC AND FACET JOINT REMOVAL IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 88 MIDDLE EAST AND AFRICA SPINAL FUSION IN ANTERIOR CERVICAL DISCECTOMY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 89 MIDDLE EAST AND AFRICA MEDIAL FACETECTOMY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 90 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET, BY INJURY TYPE, 2018-2032 (USD THOUSAND)

TABLE 91 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET, BY LEVEL OF INJURY, 2018-2032 (USD THOUSAND)

TABLE 92 MIDDLE EAST AND AFRICA CERVICAL SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 93 MIDDLE EAST AND AFRICA THORACIC SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 94 MIDDLE EAST AND AFRICA LUMBAR SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 95 MIDDLE EAST AND AFRICA SACRAL SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 96 MIDDLE EAST AND AFRICA MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 97 MIDDLE EAST AND AFRICA BRANDED IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 98 MIDDLE EAST AND AFRICA MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 99 MIDDLE EAST AND AFRICA ORAL IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 100 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 101 MIDDLE EAST AND AFRICA MALE IN SPINAL CORD INJURY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 102 MIDDLE EAST AND AFRICA FEMALE IN SPINAL CORD INJURY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 103 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 104 MIDDLE EAST AND AFRICA MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 105 SOUTH AFRICA SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 106 SOUTH AFRICA NON-OPERATIVE MANAGEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 107 SOUTH AFRICA THERAPY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 108 SOUTH AFRICA REHABILITATION THERAPY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 109 SOUTH AFRICA MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 110 SOUTH AFRICA ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 111 SOUTH AFRICA ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 112 SOUTH AFRICA ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 113 SOUTH AFRICA CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 114 SOUTH AFRICA CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 115 SOUTH AFRICA CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 116 SOUTH AFRICA ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 117 SOUTH AFRICA ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 118 SOUTH AFRICA ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 119 SOUTH AFRICA ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 120 SOUTH AFRICA ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 121 SOUTH AFRICA ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 122 SOUTH AFRICA NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 123 SOUTH AFRICA NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 124 SOUTH AFRICA NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 125 SOUTH AFRICA ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 126 SOUTH AFRICA ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 127 SOUTH AFRICA ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 128 SOUTH AFRICA OPERATIVE MANAGEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 129 SOUTH AFRICA DECOMPRESSION SURGERY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 130 SOUTH AFRICA DISC REPLACEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 131 SOUTH AFRICA DISC AND FACET JOINT REMOVAL IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 132 SOUTH AFRICA SPINAL FUSION IN ANTERIOR CERVICAL DISCECTOMY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 133 SOUTH AFRICA MEDIAL FACETECTOMY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 134 SOUTH AFRICA SPINAL CORD INJURY TREATMENT MARKET, BY INJURY TYPE, 2018-2032 (USD THOUSAND)

TABLE 135 SOUTH AFRICA SPINAL CORD INJURY TREATMENT MARKET, BY LEVEL OF INJURY, 2018-2032 (USD THOUSAND)

TABLE 136 SOUTH AFRICA CERVICAL SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 137 SOUTH AFRICA THORACIC SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 138 SOUTH AFRICA LUMBAR SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 139 SOUTH AFRICA SACRAL SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 140 SOUTH AFRICA MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 141 SOUTH AFRICA BRANDED IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 142 SOUTH AFRICA MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 143 SOUTH AFRICA ORAL IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 144 SOUTH AFRICA SPINAL CORD INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 145 SOUTH AFRICA MALE IN SPINAL CORD INJURY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 146 SOUTH AFRICA FEMALE IN SPINAL CORD INJURY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 147 SOUTH AFRICA SPINAL CORD INJURY TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 148 SOUTH AFRICA MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 149 SAUDI ARABIA SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 150 SAUDI ARABIA NON-OPERATIVE MANAGEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 151 SAUDI ARABIA THERAPY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 152 SAUDI ARABIA REHABILITATION THERAPY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 153 SAUDI ARABIA MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 154 SAUDI ARABIA ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 155 SAUDI ARABIA ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 156 SAUDI ARABIA ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 157 SAUDI ARABIA CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 158 SAUDI ARABIA CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 159 SAUDI ARABIA CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 160 SAUDI ARABIA ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 161 SAUDI ARABIA ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 162 SAUDI ARABIA ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 163 SAUDI ARABIA ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 164 SAUDI ARABIA ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 165 SAUDI ARABIA ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 166 SAUDI ARABIA NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 167 SAUDI ARABIA NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 168 SAUDI ARABIA NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 169 SAUDI ARABIA ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 170 SAUDI ARABIA ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 171 SAUDI ARABIA ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 172 SAUDI ARABIA OPERATIVE MANAGEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 173 SAUDI ARABIA DECOMPRESSION SURGERY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 174 SAUDI ARABIA DISC REPLACEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 175 SAUDI ARABIA DISC AND FACET JOINT REMOVAL IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 176 SAUDI ARABIA SPINAL FUSION IN ANTERIOR CERVICAL DISCECTOMY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 177 SAUDI ARABIA MEDIAL FACETECTOMY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 178 SAUDI ARABIA SPINAL CORD INJURY TREATMENT MARKET, BY INJURY TYPE, 2018-2032 (USD THOUSAND)

TABLE 179 SAUDI ARABIA SPINAL CORD INJURY TREATMENT MARKET, BY LEVEL OF INJURY, 2018-2032 (USD THOUSAND)

TABLE 180 SAUDI ARABIA CERVICAL SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 181 SAUDI ARABIA THORACIC SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 182 SAUDI ARABIA LUMBAR SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 183 SAUDI ARABIA SACRAL SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 184 SAUDI ARABIA MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 185 SAUDI ARABIA BRANDED IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 186 SAUDI ARABIA MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 187 SAUDI ARABIA ORAL IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 188 SAUDI ARABIA SPINAL CORD INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 189 SAUDI ARABIA MALE IN SPINAL CORD INJURY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 190 SAUDI ARABIA FEMALE IN SPINAL CORD INJURY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 191 SAUDI ARABIA SPINAL CORD INJURY TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 192 SAUDI ARABIA MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 193 U.A.E SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 194 U.A.E NON-OPERATIVE MANAGEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 195 U.A.E THERAPY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 196 U.A.E REHABILITATION THERAPY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 197 U.A.E MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 198 U.A.E ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 199 U.A.E ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 200 U.A.E ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 201 U.A.E CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 202 U.A.E CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 203 U.A.E CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 204 U.A.E ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 205 U.A.E ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 206 U.A.E ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 207 U.A.E ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 208 U.A.E ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 209 U.A.E ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 210 U.A.E NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 211 U.A.E NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 212 U.A.E NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 213 U.A.E ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 214 U.A.E ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 215 U.A.E ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 216 U.A.E OPERATIVE MANAGEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 217 U.A.E DECOMPRESSION SURGERY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 218 U.A.E DISC REPLACEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 219 U.A.E DISC AND FACET JOINT REMOVAL IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 220 U.A.E SPINAL FUSION IN ANTERIOR CERVICAL DISCECTOMY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 221 U.A.E MEDIAL FACETECTOMY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 222 U.A.E SPINAL CORD INJURY TREATMENT MARKET, BY INJURY TYPE, 2018-2032 (USD THOUSAND)

TABLE 223 U.A.E SPINAL CORD INJURY TREATMENT MARKET, BY LEVEL OF INJURY, 2018-2032 (USD THOUSAND)

TABLE 224 U.A.E CERVICAL SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 225 U.A.E THORACIC SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 226 U.A.E LUMBAR SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 227 U.A.E SACRAL SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 228 U.A.E MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 229 U.A.E BRANDED IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 230 U.A.E MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 231 U.A.E ORAL IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 232 U.A.E SPINAL CORD INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 233 U.A.E MALE IN SPINAL CORD INJURY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 234 U.A.E FEMALE IN SPINAL CORD INJURY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 235 U.A.E SPINAL CORD INJURY TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 236 U.A.E MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 237 EGYPT SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 238 EGYPT NON-OPERATIVE MANAGEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 239 EGYPT THERAPY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 240 EGYPT REHABILITATION THERAPY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 241 EGYPT MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 242 EGYPT ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 243 EGYPT ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 244 EGYPT ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 245 EGYPT CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 246 EGYPT CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 247 EGYPT CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 248 EGYPT ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 249 EGYPT ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 250 EGYPT ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 251 EGYPT ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 252 EGYPT ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 253 EGYPT ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 254 EGYPT NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 255 EGYPT NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 256 EGYPT NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 257 EGYPT ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 258 EGYPT ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 259 EGYPT ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 260 EGYPT OPERATIVE MANAGEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 261 EGYPT DECOMPRESSION SURGERY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 262 EGYPT DISC REPLACEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 263 EGYPT DISC AND FACET JOINT REMOVAL IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 264 EGYPT SPINAL FUSION IN ANTERIOR CERVICAL DISCECTOMY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 265 EGYPT MEDIAL FACETECTOMY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 266 EGYPT SPINAL CORD INJURY TREATMENT MARKET, BY INJURY TYPE, 2018-2032 (USD THOUSAND)

TABLE 267 EGYPT SPINAL CORD INJURY TREATMENT MARKET, BY LEVEL OF INJURY, 2018-2032 (USD THOUSAND)

TABLE 268 EGYPT CERVICAL SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 269 EGYPT THORACIC SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 270 EGYPT LUMBAR SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 271 EGYPT SACRAL SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 272 EGYPT MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 273 EGYPT BRANDED IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 274 EGYPT MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 275 EGYPT ORAL IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 276 EGYPT SPINAL CORD INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 277 EGYPT MALE IN SPINAL CORD INJURY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 278 EGYPT FEMALE IN SPINAL CORD INJURY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 279 EGYPT SPINAL CORD INJURY TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 280 EGYPT MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 281 KUWAIT SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 282 KUWAIT NON-OPERATIVE MANAGEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 283 KUWAIT THERAPY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 284 KUWAIT REHABILITATION THERAPY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 285 KUWAIT MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 286 KUWAIT ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 287 KUWAIT ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 288 KUWAIT ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 289 KUWAIT CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 290 KUWAIT CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 291 KUWAIT CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 292 KUWAIT ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 293 KUWAIT ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 294 KUWAIT ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 295 KUWAIT ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 296 KUWAIT ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 297 KUWAIT ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 298 KUWAIT NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 299 KUWAIT NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 300 KUWAIT NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 301 KUWAIT ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 302 KUWAIT ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 303 KUWAIT ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 304 KUWAIT OPERATIVE MANAGEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 305 KUWAIT DECOMPRESSION SURGERY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 306 KUWAIT DISC REPLACEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 307 KUWAIT DISC AND FACET JOINT REMOVAL IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 308 KUWAIT SPINAL FUSION IN ANTERIOR CERVICAL DISCECTOMY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 309 KUWAIT MEDIAL FACETECTOMY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 310 KUWAIT SPINAL CORD INJURY TREATMENT MARKET, BY INJURY TYPE, 2018-2032 (USD THOUSAND)

TABLE 311 KUWAIT SPINAL CORD INJURY TREATMENT MARKET, BY LEVEL OF INJURY, 2018-2032 (USD THOUSAND)

TABLE 312 KUWAIT CERVICAL SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 313 KUWAIT THORACIC SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 314 KUWAIT LUMBAR SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 315 KUWAIT SACRAL SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 316 KUWAIT MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 317 KUWAIT BRANDED IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 318 KUWAIT MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 319 KUWAIT ORAL IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 320 KUWAIT SPINAL CORD INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 321 KUWAIT MALE IN SPINAL CORD INJURY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 322 KUWAIT FEMALE IN SPINAL CORD INJURY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 323 KUWAIT SPINAL CORD INJURY TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 324 KUWAIT MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 325 QATAR SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 326 QATAR NON-OPERATIVE MANAGEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 327 QATAR THERAPY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 328 QATAR REHABILITATION THERAPY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 329 QATAR MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 330 QATAR ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 331 QATAR ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 332 QATAR ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 333 QATAR CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 334 QATAR CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 335 QATAR CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 336 QATAR ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 337 QATAR ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 338 QATAR ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 339 QATAR ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 340 QATAR ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 341 QATAR ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 342 QATAR NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 343 QATAR NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 344 QATAR NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 345 QATAR ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 346 QATAR ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 347 QATAR ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 348 QATAR OPERATIVE MANAGEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 349 QATAR DECOMPRESSION SURGERY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 350 QATAR DISC REPLACEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 351 QATAR DISC AND FACET JOINT REMOVAL IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 352 QATAR SPINAL FUSION IN ANTERIOR CERVICAL DISCECTOMY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 353 QATAR MEDIAL FACETECTOMY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 354 QATAR SPINAL CORD INJURY TREATMENT MARKET, BY INJURY TYPE, 2018-2032 (USD THOUSAND)

TABLE 355 QATAR SPINAL CORD INJURY TREATMENT MARKET, BY LEVEL OF INJURY, 2018-2032 (USD THOUSAND)

TABLE 356 QATAR CERVICAL SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 357 QATAR THORACIC SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 358 QATAR LUMBAR SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 359 QATAR SACRAL SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 360 QATAR MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 361 QATAR BRANDED IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 362 QATAR MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 363 QATAR ORAL IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 364 QATAR SPINAL CORD INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 365 QATAR MALE IN SPINAL CORD INJURY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 366 QATAR FEMALE IN SPINAL CORD INJURY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 367 QATAR SPINAL CORD INJURY TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 368 QATAR MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 369 OMAN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 370 OMAN NON-OPERATIVE MANAGEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 371 OMAN THERAPY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 372 OMAN REHABILITATION THERAPY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 373 OMAN MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 374 OMAN ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 375 OMAN ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 376 OMAN ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 377 OMAN CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 378 OMAN CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 379 OMAN CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 380 OMAN ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 381 OMAN ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 382 OMAN ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 383 OMAN ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 384 OMAN ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 385 OMAN ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 386 OMAN NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 387 OMAN NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 388 OMAN NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 389 OMAN ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 390 OMAN ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 391 OMAN ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 392 OMAN OPERATIVE MANAGEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 393 OMAN DECOMPRESSION SURGERY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 394 OMAN DISC REPLACEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 395 OMAN DISC AND FACET JOINT REMOVAL IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 396 OMAN SPINAL FUSION IN ANTERIOR CERVICAL DISCECTOMY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 397 OMAN MEDIAL FACETECTOMY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 398 OMAN SPINAL CORD INJURY TREATMENT MARKET, BY INJURY TYPE, 2018-2032 (USD THOUSAND)

TABLE 399 OMAN SPINAL CORD INJURY TREATMENT MARKET, BY LEVEL OF INJURY, 2018-2032 (USD THOUSAND)

TABLE 400 OMAN CERVICAL SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 401 OMAN THORACIC SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 402 OMAN LUMBAR SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 403 OMAN SACRAL SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 404 OMAN MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 405 OMAN BRANDED IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 406 OMAN MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 407 OMAN ORAL IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 408 OMAN SPINAL CORD INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 409 OMAN MALE IN SPINAL CORD INJURY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 410 OMAN FEMALE IN SPINAL CORD INJURY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 411 OMAN SPINAL CORD INJURY TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 412 OMAN MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 413 BAHRAIN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 414 BAHRAIN NON-OPERATIVE MANAGEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 415 BAHRAIN THERAPY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 416 BAHRAIN REHABILITATION THERAPY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 417 BAHRAIN MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 418 BAHRAIN ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 419 BAHRAIN ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 420 BAHRAIN ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 421 BAHRAIN CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 422 BAHRAIN CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 423 BAHRAIN CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 424 BAHRAIN ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 425 BAHRAIN ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 426 BAHRAIN ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 427 BAHRAIN ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 428 BAHRAIN ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 429 BAHRAIN ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 430 BAHRAIN NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 431 BAHRAIN NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 432 BAHRAIN NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 433 BAHRAIN ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 434 BAHRAIN ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)

TABLE 435 BAHRAIN ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)

TABLE 436 BAHRAIN OPERATIVE MANAGEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 437 BAHRAIN DECOMPRESSION SURGERY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 438 BAHRAIN DISC REPLACEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 439 BAHRAIN DISC AND FACET JOINT REMOVAL IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 440 BAHRAIN SPINAL FUSION IN ANTERIOR CERVICAL DISCECTOMY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 441 BAHRAIN MEDIAL FACETECTOMY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 442 BAHRAIN SPINAL CORD INJURY TREATMENT MARKET, BY INJURY TYPE, 2018-2032 (USD THOUSAND)

TABLE 443 BAHRAIN SPINAL CORD INJURY TREATMENT MARKET, BY LEVEL OF INJURY, 2018-2032 (USD THOUSAND)

TABLE 444 BAHRAIN CERVICAL SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 445 BAHRAIN THORACIC SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 446 BAHRAIN LUMBAR SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 447 BAHRAIN SACRAL SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 448 BAHRAIN MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 449 BAHRAIN BRANDED IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 450 BAHRAIN MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 451 BAHRAIN ORAL IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 452 BAHRAIN SPINAL CORD INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 453 BAHRAIN MALE IN SPINAL CORD INJURY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 454 BAHRAIN FEMALE IN SPINAL CORD INJURY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 455 BAHRAIN SPINAL CORD INJURY TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 456 BAHRAIN MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 457 REST OF MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

Liste des figures

FIGURE 1 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 8 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET: SEGMENTATION

FIGURE 11 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET EXECUTIVE SUMMARY

FIGURE 12 STRATEGIC DECISIONS

FIGURE 13 TWO SEGMENTS COMPRISE THE MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET, BY TYPE

FIGURE 14 GROWING COLLABORATION AND EXPANDING PARTNERSHIPS IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET GROWTH IN THE FORECAST PERIOD OF 2025 TO 2032

FIGURE 15 NON-OPERATIVE MANAGEMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT IN THE FORECAST PERIOD OF 2025 & 2032

FIGURE 16 MARKET OVERVIEW

FIGURE 17 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET: BY TYPE, 2024

FIGURE 18 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET: BY TYPE, 2025-2032 (USD THOUSAND)

FIGURE 19 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET: BY TYPE, CAGR (2025-2032)

FIGURE 20 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET: BY TYPE, LIFELINE CURVE

FIGURE 21 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET: BY LEVEL OF INJURY, 2024

FIGURE 22 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET: BY LEVEL OF INJURY, 2025-2032 (USD THOUSAND)

FIGURE 23 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET: BY LEVEL OF INJURY, CAGR (2025-2032)

FIGURE 24 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET: BY LEVEL OF INJURY, LIFELINE CURVE

FIGURE 25 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET: BY INJURY TYPE, 2024

FIGURE 26 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET: BY INJURY TYPE, 2025-2032 (USD THOUSAND)

FIGURE 27 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET: BY INJURY TYPE, CAGR (2025-2032)

FIGURE 28 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET: BY INJURY TYPE, LIFELINE CURVE

FIGURE 29 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET: BY GENDER, 2024

FIGURE 30 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET: BY GENDER, 2025-2032 (USD THOUSAND)

FIGURE 31 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET: BY GENDER, CAGR (2025-2032)

FIGURE 32 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET: BY GENDER, LIFELINE CURVE

FIGURE 33 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET: BY END USER, 2024

FIGURE 34 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET: BY END USER, 2025-2032 (USD THOUSAND)

FIGURE 35 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET: BY END USER, CAGR (2025-2032)

FIGURE 36 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 37 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET: SNAPSHOT (2024)

FIGURE 38 MIDDLE EAST AND AFRICA SPINAL CORD INJURY TREATMENT MARKET: COMPANY SHARE 2024 (%)

Voir les informations détaillées

Méthodologie de recherche

La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.

La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.

Personnalisation disponible

Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.

Questions fréquemment posées

Quels sont les principaux segments couverts dans le rapport Middle East and Africa Spinal Cord Injury Treatment Market ?

Le marché est segmenté en fonction de Middle East and Africa Spinal Cord Injury Treatment Market, By Type (Non-Operative Management and Operative Management), Injury Type (Complete Spinal Cord Injuries and Partial Spinal Cord Injuries), Level of Injury (Cervical Spinal Cord Injuries, Thoracic Spinal Cord Injuries, Lumbar Spinal Cord Injuries, and Sacral Spinal Cord Injuries), Gender (Male and Female), End User (Hospitals, Trauma Centers, Specialty Clinics, Clinics, Ambulatory and Research Centers, and Others) - Industry Trends & Forecast To 2032 .

Quelle est la taille actuelle du marché de Middle East and Africa Spinal Cord Injury Treatment Market ?

La taille du Middle East and Africa Spinal Cord Injury Treatment Market était estimée à 249.49 USD Million USD en 2024.

Quel est le taux de croissance prévu du Middle East and Africa Spinal Cord Injury Treatment Market ?

Le Middle East and Africa Spinal Cord Injury Treatment Market devrait croître à un TCAC de 3.9% sur la période de prévision de 2025 à 2032.

Qui sont les principaux acteurs du Middle East and Africa Spinal Cord Injury Treatment Market ?

Les principaux acteurs du marché sont Novartis AG, Pfizer Inc., Medtronic, Zimmer Biomet, Abbott, Amneal Pharmaceuticals LLC, Sanofi, Axonis Therapeutics.

Middle East and Africa Spinal Cord Injury Treatment Market – Industry Trends and Forecast to 2032

Contournez les défis liés aux tarifs grâce à un conseil agile en chaîne d'approvisionnement

Middle East And Africa Spinal Cord Injury Treatment Market

TCAC : 3.90 %

Middle East and Africa Spinal Cord Injury Treatment Market Analysis

Middle East and Africa Spinal Cord Injury Treatment Market Size

Middle East and Africa Spinal Cord Injury Treatment Market Scope

Analyse régionale du marché du traitement des lésions de la moelle épinière au Moyen-Orient et en Afrique

Part de marché du traitement des lésions de la moelle épinière au Moyen-Orient et en Afrique

Derniers développements sur le marché du traitement des lésions de la moelle épinière au Moyen-Orient et en Afrique

Accédez en ligne au rapport sur le premier cloud mondial de veille économique

Table des matières

Liste des tableaux

Liste des figures

Méthodologie de recherche

Personnalisation disponible

Questions fréquemment posées

Rapports

Aperçus du marché

Soutien

Solutions

Middle East and Africa Spinal Cord Injury Treatment Market – Industry Trends and Forecast to 2032

Contournez les défis liés aux tarifs grâce à un conseil agile en chaîne d'approvisionnement

Middle East And Africa Spinal Cord Injury Treatment Market

TCAC : 3.90 %

Middle East and Africa Spinal Cord Injury Treatment Market Analysis

Middle East and Africa Spinal Cord Injury Treatment Market Size

Middle East and Africa Spinal Cord Injury Treatment Market Scope

Analyse régionale du marché du traitement des lésions de la moelle épinière au Moyen-Orient et en Afrique

Part de marché du traitement des lésions de la moelle épinière au Moyen-Orient et en Afrique

Derniers développements sur le marché du traitement des lésions de la moelle épinière au Moyen-Orient et en Afrique

Accédez en ligne au rapport sur le premier cloud mondial de veille économique

Table des matières

Liste des tableaux

Liste des figures

Méthodologie de recherche

Personnalisation disponible

Questions fréquemment posées

Parcourir les pages associées